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Recent developments in the field of mitochondrial replacement technique (MRT) research and clinical 
practice have raised ethical concerns worldwide. We argue that the future use of MRTs requires a 
concerted effort among the global research and clinical community to implement and enforce 
responsible innovation and governance. 
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Mitochondrial replacement techniques (MRTs) have been developed to help women who are 
carriers of harmful mitochondrial DNA (mtDNA) mutations to have healthy, genetically 
related offspring. MRTs involve the transfer of the nuclear DNA of a woman’s oocyte carrying 
an mtDNA mutation into a donor oocyte carrying healthy mitochondria. The transfer can be 
performed either before in vitro fertilization (by transferring the spindle complex of diseased 
oocytes, i.e. maternal spindle transfer) or after (by transferring the pronuclei of the affected 
woman’s zygote, i.e. pronuclear transfer). Since mitochondria are maternally inherited, such 
transfers would in theory prevent maternal transmission of mtDNA disease while preserving 
the genetic link between affected mothers and their offspring (Bredenoord and Hyun, 2015). 
The use of MRTs is particularly controversial because it is a form of germline modification.  
 
In recent years, several scientific, ethical, and political bodies have tried to grasp the various 
implications of MRTs. It now appears that the technique is gaining momentum politically and 
scientifically. In January 2017, the UK became the first country to license the clinical use of 
an MRT when the Newcastle Fertility Centre was granted a license by the Human Fertilisation 
and Embryology Authority to use pronuclear transfer. However, this was only after the first 
baby born through MRT had been revealed to the world in 2016. This ‘‘world first’’ was 
accomplished by clinicians taking a regulatory detour by carrying out the MRT (which in this 
case was maternal spindle transfer) in their New York City clinic and then shipping the embryo 




regulatory issues (Palacios-Gonzaález and Medina-Arellano, 2017; Zhang et al., 2017). In 
addition, in Ukraine a baby has been created via MRT and born (as reported in New Scientist 
earlier this year), albeit not for disease prevention but to rejuvenate the fertility of aging 
oocytes. It is also likely that MRTs will be accompanied in the clinic by some broader advances 
in biomedicine, including the emergence of CRISPR/Cas9-mediated genome editing and stem-
cell derived gametes.  
 
In this Forum, we evaluate the ethical implications of recent developments in the field of MRT 
research and clinical practice. We argue that despite some clinical success surrounding the 
creation of babies with MRTs, this may come at the cost of encouraging the irresponsible use 
of new assisted reproductive and genetic technologies. We support the use of MRTs, but do so 
with the view that they should be used cautiously. In light of the remaining ethical challenges 
that still exist surrounding MRTs, we maintain that the future use of MRTs requires a concerted 
effort among the global research and clinical community to put in place responsible innovation 
and governance of these techniques. 
 
Governance: Updates on Key Reports, Policy, and Regulations 
 
In 2015 the UK was the first country to implement a set of laws—The Human Fertilisation and 
Embryology (Mitochondrial Donation) Regulations 2015—specifically devised to regulate 
MRTs (both maternal spindle transfer and pronuclear transfer) for applications in human 
research and clinical practice. However, the path to the UK’s governance of MRTs was a 
culmination of several years of public consultations and publications that were regularly 
marked by debate and controversy (Appleby, 2015).  
 
While the UK’s laws are not a panacea, they do set out some basic parameters that must be 
followed in order for the use of an MRT to be licensed and which improve the likelihood that 
the techniques will be used safely and effectively. For instance, a license can only be granted 
for use in cases where it has been determined that there is a particular and significant risk that 
a prospective child will inherit a serious mitochondrial disease. Also, clinics seeking a license 
must provide a plan to follow up with any future children in order to monitor their wellbeing.  
 
Discussion surrounding the regulation and policy aspects of MRTs has also taken place in the 
US. In 2016 a US FDA commissioned report from the US National Academy of Science’s 
Institute of Medicine was published, entitled Mitochondrial Replacement Techniques: Ethical, 
Social, and Policy Considerations. This report lays out a range of recommendations about how 
US researchers and clinicians should proceed with the clinical use of MRTs. There are areas 
where its recommendations conflict with the regulations and views of UK policymakers. For 
instance, unlike the UK, the US report recommends the use of sex selection to select for male 
embryos and for MRTs to be introduced into clinical practice via clinical research. While the 
US report outlines a somewhat more cautious approach to the introduction of MRTs, both the 
UK and US share similar perspectives with respect to the safe governance of MRTs, including 
the need to gather data on the outcomes of MRT pregnancies and births, the need to only use 
MRTs if serious mitochondrial diseases are unavoidable, and the need to minimize risks to 
future children.  
 
Despite some political and social attitude differences toward the use of novel assisted and 
genetic technologies (Bredenoord and Hyun, 2015), it is significant that both the UK and the 
US have ethically endorsed the clinical use of MRTs for mtDNA disease and that each country 




as confirmed by the UK Department of Health (Appleby, 2015) and a recent National 
Academies of Science, Engineering and Medicine report (2017), a key distinction that must be 
noted is that germline modification refers to the replacement of an intact germline genome, 
rather than the modification of genes within a germline genome. While the endorsement of 
germline modification is a significant milestone with respect to changing attitudes in science 
regulation and policy, modifying the genes within the human germline genome is likely to 
continuously raise fierce scientific and ethical debates. If a time comes wherein modifying the 
genes within the human germline genome is deemed acceptable, the conditions under which it 
is permissible will need to be determined through a process that is rigorous and transparent. 
 
Remaining Ethical Challenges Mexico and Ukraine: Premature Clinical Applications? 
 
Several other ethical challenges remain surrounding the clinical use of MRTs. An initial 
question is when MRTs should be moved to the clinic. The UK and US have demonstrated that 
expert debate with public involvement is valuable and that governance of MRTs can be 
achieved. This makes the first clinical applications in Mexico and Ukraine morally 
questionable. The teams of clinicians in both Mexico and the Ukraine each proceeded to create 
MRT-conceived babies in the absence of specific governance surrounding the use of MRTs. 
Fortunately, both procedures resulted in healthy babies, at least so far. After all, the mutation 
load in the newborn baby created in Mexico was further analyzed and showed defective 
mitochondria ranging from undetectable in placenta, umbilical blood, and umbilical cord to 
2.36% in urine precipitate, 3.52% in buccal epithelium, 5.59% in hair follicles, 6.77% in 
amnion, and 9.23% in the circumcised foreskin (Zhang et al., 2017). This indicates that the risk 
for developing mtDNA disease is drastically reduced, but cannot be completely excluded. But 
even if completely eliminating this risk could be possible, then seeking areas of low governance 
does not appear to be the way forward for novel reproductive and genetic technologies. This 
stricter outlook is suggested by a recent FDA warning letter to Dr. Zhang, who led the 
procedure in Mexico. 
 
The application of new medical technologies always requires finding a balance between 
cavalier practice and opportunity costs, between laissez-faire and overregulation. Initial 
applications of novel reproductive and genetic technology should at least be aimed at 
generating novel knowledge. The European Society for Human Reproduction and Embryology 
(ESHRE) and other professional organizations have condemned hasty ‘‘try it and see’’ 
approaches. In particular, reproductive medicine has a history of introducing innovations into 
clinical practice without proper preclinical research into their effectiveness and safety, such as 
embryo and oocyte cryopreservation, intracytoplasmic sperm injection (ICSI), and ooplasm 
transfer (Dondorp and de Wert, 2011). What we are currently witnessing in the case of MRTs 
is part of this ongoing historical narrative of clinicians offering a new reproductive treatment 
outside of formal research routes. One could argue that (fortunately) after decades of 
innovation, no patterns of serious safety problems have emerged from the use of IVF and other 
reproductive treatments; however, a strong case can be made for a more ambitious approach to 
innovation than this field of medicine has shown to date (Dondorp and de Wert, 2011), 
particularly as we enter the era of germline modifications.  
 
The Mexican and Ukrainian events may have complex implications for these countries and 
elsewhere (Palacios-González and Medina-Arellano, 2017). For example, politicians in 
Mexico have already announced that they will initiate laws to restrict MRT. In addition, any 
substandard clinical application could jeopardize approval in other countries. For example, the 




due process and governance, thus, sending the wrong message that these techniques can be 
used elsewhere to avoid regulatory processes. This could undermine public trust, undermine 
policy making, and fuel a ‘‘race to the bottom’’ for new biomedical technologies. Therefore, 
the development and implementation of collective global governance is part of the global 
research community’s responsibility to ensure that radically new biotechnologies such as 
MRTs (and future techniques, such as stem cell-derived gametes) are delivered safely and 
effectively to those who access them. 
 
We also need to reflect on the ethics of alternative clinical applications of MRTs that are 
beginning to (re)emerge. For example, the recent MRT (pronuclear transfer) use in Ukraine 
was not to avoid a significant risk of serious disease in offspring, but instead to rejuvenate the 
fertility of aging oocytes, similar to the way that cytoplasmic transfer was used to treat 
infertility from 1997 to 2001 in the US before the FDA banned its use in 2001 (Appleby, 2015). 
We question the ethical permissibility of using these experimental techniques outside a 
research setting in cases where a prospective person is not at any risk of inheriting a serious 
disease. The acceptability of offering an experimental fertility procedure without sufficient 
scientific basis, oversight, and scientific follow-up is comparable with stem cell clinics that 
offer unproven stem cell ‘‘treatments,’’ thereby exploiting the hope of often seriously ill 
patients. The fact that these alternative commercial uses of MRTs have been carried out in 
nations lacking proper regulation and rigorous oversight into MRTs further strengthens our 
core argument that there is a global responsibility within the research community to discourage 
premature use of experimental techniques, such as MRTs, and to strive for robust governance 
in areas where it is currently lacking.  
 
MRTs and Donor Anonymity  
 
The status (i.e., anonymous or non-anonymous) of mitochondrial donors was among the most 
discussed and controversial aspects of the UK’s recent public consultation that led up to the 
regulation of mitochondrial donation and MRTs. Unsurprisingly, there has been continued 
academic debate surrounding the anonymity of mitochondrial donors in the UK since the 
regulation of these techniques (Haimes and Taylor, 2017; Turkmendag, 2017) and it is likely 
that this debate will continue to grow as additional countries consider the governance and use 
of MRTs.  
 
According to UK MRT regulations, mitochondrial donors will remain anonymous, unlike 
gamete, oocyte, and embryo donors, which are identifiable to offspring after the latter reach 
the age of 18. It could be argued that the UK government’s reasoning for allowing 
mitochondrial donor anonymity is inconsistent. One possible argument against the government 
policy is that mitochondrial donors should not be treated differently from gamete and embryo 
donors because the mere fact that mitochondria have a different quantity of genes in their 
genome (the quantity claim), and the fact that qualities of the genes are not responsible for the 
phenotypic expression of our ‘‘personal characteristics’’ (the quality claim), does not 
necessarily mean that the identity of the person who donated them would be of less interest to 
the person created with them. While the mitochondrial genome may be fungible, it nevertheless 
constitutes a fundamental part of an individual’s healthy functioning body and contributes to 
the nature of their appearance and their course of life (Bredenoord et al., 2011). Therefore, a 
fresh debate informed by social science evidence (including evidence from other relevant areas 
of assisted reproduction) needs to be conducted about whether or not having anonymous 





MRTs and the Value of Genetic Relatedness 
 
One additional remaining ethical issue is whether or not MRTs further reinforce the social 
value of genetic relatedness. The main reason prospective parents want to use MRTs is to have 
a genetically related child; otherwise, they could use donated oocytes or embryos, which are 
known to be a safe form of assisted reproduction. This area of the MRT debate raises an 
important question: why is genetic relatedness of value? With the emergence of gene editing 
technologies and stem cell-derived gametes, it may become possible to create offspring who 
have inherited genes of many different quantities and qualities (Bredenoord and Hyun, 2017). 
Techniques such as MRTs have disrupted our paradigm of what kinds of genetic relatedness 
should matter and society must now revisit why we place importance on whether or not we 
share certain quantities and qualities of genes with others. Our conclusions to these questions 
may influence future policies surrounding issues such as the status of donors of genetic 
materials in reproduction and how many individuals we may permit to genetically contribute 




Given the considerable number of remaining ethical questions surrounding the use of MRTs, 
the global community of researchers has a responsibility to encourage, foster, and implement 
the necessary governance of these techniques to ensure that they are used effectively, safely, 
and responsibly. The use of MRTs can and should be viewed as an opportunity for learning 
and a model for how morally sound governance can be achieved for other innovative 
reproductive and genetic technologies in the future, including germline genome editing and 
stem cell-derived gametes.  
 
As genome editing techniques improve and might move into the realm of human reproduction, 
it is also necessary to consider the ethical implications these techniques might have if coupled 
with MRTs or if they are eventually used to replace MRTs altogether. If these technologies 
become more effective and eventually become a feasible option for treating inheritable genetic 
conditions in embryos in vitro, global attitudes to the use of these techniques may adjust in the 
same way that they have for MRTs.  
 
In view of the variety of legislative and regulatory jurisdictions throughout the world and even 
within nations, legal harmonization for MRTs is unlikely and possibly also undesirable. After 
all, how biotechnology regulations are framed is inevitably shaped by (political) culture and 
context. However, what is both necessary and possible is the development of ethical principles 
to guide our research. Historically, some powerful examples exist of where the international 
community has successfully developed international guidelines for ethical conduct in research, 
such as the WMA Declaration of Helsinki and the CIOMS International Ethical Guidelines for 
Health-related Research Involving Humans. These guidelines clearly are moral guidelines, 
meaning that they entail shared moral principles that countries can voluntarily use to help frame 
their local regulations. Their concomitant adoption by funding agencies, research institutes, 
and editorial policies, as has been done over the years by the Declaration of Helsinki, will 
contribute to the achievement of some form of improved global bioethics governance. It is a 
mistaken and even dangerous view to perceive science and biotechnology as autonomous 
forces that cannot be governed (Jasanoff, 2016).  
 
Responsible innovation only amounts to empty rhetoric if it is not actively supported and 




what the scientific community therefore needs is something along the lines of a modern 
‘‘Reproductive Asilomar,’’ where the scientific, ethical, and societal challenges of novel 
reproductive and genetic technologies are explored and discussed in a deliberative, inclusive 
international forum. In this way, science, technology, ethics, and society could be more co-
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